Sunday July 12, 2020 10:35

Heathcare Press Release : 14 May 2020

A virology guru says meat is safe for consumption despite COVID-19 outbreak Heathcare—14 May 20

A virology guru reassures it is safe to eat fully cooked meat, for example, pork, chicken and duck, amid COVID-19 pandemic. “According to the research from China, COVID-19 cannot be transmitted to farmed animals like pig, chicken and duck,”

Halodine(R) Nasal and Oral Antiseptics Show Rapid Antiviral Activity Against SARS-CoV-2 (COVID-19) Heathcare—14 May 20

FORT LAUDERDALE Florida--14 May--PRNewswire/InfoQuest

Veloce BioPharma LLC reports today that their Halodine(R) Antiseptics have demonstrated rapid viricidal efficacy against SARS-CoV-2, the virus that causes COVID-19. Halodine(R) is a proprietary povidone-iodine antiseptic developed in partnership with leading clinicians for repeated nasal and oral administration. In experiments conducted with The Institute for Antiviral Research at Utah State University, a BSL3+ laboratory, the proprietary Halodine(R) nasal and oral antiseptic preparations were proven to rapidly inactivate SARS-CoV-2. It has been proven to be effective against SARS-CoV-2 even at dilutions as low as 1/20 of the commercially available solutions.

"This study shows that a non-toxic nasal and oral solution is also effective against SARS-CoV-2. This is the first iodine-based antiseptic that has ever been shown to have activity against the virus that causes COVID-19," said lead author Jesse Pelletier MD FACS, of Ocean Ophthalmology Group (Miami, FL). "Now that we finally have proven efficacy against SARS-CoV-2 for povidone-iodine solutions that are safe for mucosa, we can incorporate them in to our COVID-19 transmission reduction efforts." Dr. Pelletier is leading efforts to design safe return-to-work protocols for ophthalmology outpatient clinics and ambulatory surgery centers.

Halodine (R) and C

Hetero Enters Into a Licensing Agreement With Gilead Sciences, Inc. for the Manufacturing and Heathcare—14 May 20

Hetero, one of India's leading generic pharmaceutical companies and the world's largest producer of anti-retroviral drugs, announced today that it has entered into a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of

Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Heathcare—14 May 20

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (and hereafter referred to as "Cipla") today announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine

DERMALOG Fever Detection Protects Dragerwerk AG Production Heathcare—14 May 20

- Despite Covid-19, assembly lines in many factories do not stop. Production at Drager is also in full operation. As a manufacturer of ventilators, the German company's products are currently in high demand. To keep the risk of infection among employees

Fluxergy Announces $30 Million to Expand Manufacturing Capacity of Its One-hour Point-of-care Heathcare—14 May 20

Irvine, California-based Fluxergy LLC, a diagnostic test company, is making a $30 million investment to expand its capability to scale production of the Fluxergy Analyzer diagnostic testing system in response to the COVID-19 pandemic. The Fluxergy

Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO Heathcare—14 May 20

- Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa?